Rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate are driving the growth of the global Human Microbiome Market. The market is an emerging market with abundant opportunities and is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase.
Europe is expected to dominate the human microbiome market during the study period
Europe is expected to account for the largest share of the human microbiome market in 2022. The large share of this region can be attributed to the rising incidence of chronic and lifestyle diseases, high awareness and acceptance of microbiome-based products, and the high awareness of personalized medicine in this region.
Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.) are the major players in the human microbiome market. Domination of the individual segments in this market will depend on the core competencies of different players.
Download PDF Brochure for More Details@
Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.
Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals.
To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors. Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions. The company provides products and technologies in the emerging areas of disease management for human gut microbiome and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel disease, metabolic diseases, and related disorders.
In-depth research into the human microbiome market revealed that agreements, partnerships, and collaborations were the key strategies adopted by major players to enter the microbiome business or expand their microbiome business units.
Major players that adopted this strategy include Second Genome (U.S.), Enterome Bioscience (France), Vedanta Bioscience (U.S.), and Osel, Inc. (U.S.). In April 2016, Enterome entered an agreement with Vertex Pharmaceuticals Inc. (U.S.) to research, develop, and commercialize novel small molecule FimH antagonists, to be utilized in the treatment of inflammatory bowel diseases (IBD).
Companies in the Asia-Pacific regions are also entering the field of microbiome. Yakult Honsha Co., Ltd. is one such company which is engaged in manufacturing and marketing food and beverage products. The company operates through three business segments, namely, Food and Beverages, Pharmaceuticals, and Others. The Food and Beverages segment includes juices, soft drinks, and healthy foods. This segment also includes probiotic drinks that contain Lactobacillus casei, a bacterium which improves intestinal function and immunity.